Please provide your email address to receive an email when new articles are posted on . Phase 3 clinical trial included 134 adults with full neuroaxis MRI and no new NMOSD symptoms. At 28 weeks, 15% ...

Starting treatment for multiple sclerosis early — before symptoms even begin — could possibly delay the onset of the condition, new research finds. Preliminary results of a small Phase 3 clinical ...

—In a new study, the extent of microstructural damage in patients with early relapsing-remitting multiple sclerosis (RRMS) was associated with worse disability and spinal cord atrophy at 5 years. Here ...

In a new study in mice, a team of researchers from UCLA, the Swiss Federal Institute of Technology, and Harvard University have uncovered a crucial component for restoring functional activity after ...

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the ...

A large, multidisciplinary team led by researchers from Texas A&M University has made a potentially game-changing discovery ...

In samples of the spinal cord from four deceased MS patients, 260 genes were simultaneously analyzed and the cellular architecture of the lesions could be determined. The authors also found new ...

Clinical Presentation Common symptoms of NMOSD result from damage to the optic nerve, spinal cord, and brainstem. These include optic neuritis with symptoms of loss or blurred vision in 1 or both eyes ...

BUFFALO, N.Y. – Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an ...

Collaborating scientists at the Karolinska Institute and at Stockholm University used a technology called in situ sequencing (ISS) to help reveal at the cellular level how lesions in multiple ...